Why intellectual property rights matter for COVID-19
The IP system has been crucial in underpinning the research, development and manufacture of vaccines and therapeutics for COVID-19, proving critics of IP wrong at every step of this crisis.
Overcoming obstacles to medicines access
As the 2020 World Health Assembly re-convenes in Geneva, an international coalition of think tanks urges governments to commit to simple reforms to accelerate access to medicines, including those in the process of being developed for Covid-19.
Watch: How intellectual property rights are helping to beat Covid-19
Experts from the life science and research community explain the crucial role of intellectual property rights in developing new vaccines and therapeutics for Covid-19.
Towards a more focused, less divisive World Health Organization
The WHO has a crucial role in coordinating the global response to pandemics and health emergencies, but this important work is undermined by strategic incoherence and an ideological approach to policymaking.
Superar los obstáculos para el acceso a los medicamentos
Somos una coalición internacional de institutos de investigación de políticas públicas y grupos de reflexión que cree que la colaboración, el comercio libre y la innovación son cruciales para la respuesta al Covid-19.
VIDEO: Los derechos de propiedad intelectual ayudan a derrotar a la Covid-19
Expertos de la comunidad de las biociencias y la investigación explican el rol fundamental que juegan los derechos de propiedad intelectual en el desarrollo de vacunas y tratamientos contra la Covid-19.
Geneva Network contribution to the EC’s Pharmaceutical Strategy Roadmap
Geneva Network and allied think tanks have written to the European Commission calling for innovation to be at the heart of its Pharmaceutical Strategy.
The innovation paradox: why complex drug research is not being rewarded
The patent system in the US and the EU is not rewarding complex research into treatments for a host of prevalent diseases and conditions, and reforms are going in the wrong direction, says Erika Lietzan of the University of Missouri School of Law.
Don’t Let Life Sciences Innovation Become Another Coronavirus Casualty
Traditional rivals within the life sciences industry have pledged to cooperate by sharing data, patent libraries, and, if necessary, manufacturing capacity.